FindTrial
Sign In

Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma - ND

Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-004751-38-IT
Enrollment
Unknown
Registered
2009-05-13
Start date
2004-02-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney carcinoma MedDRA version: 6.1 Level: PT Classification code 10038415

Interventions

Pharmaceutical Form: Emulsion for injection Current Sponsor code: DC dendritic cell Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 1000000-

Sponsors

OSPEDALE ONCOLOGICO DI BARI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with hystologically proved MRCC 2. Good performance status 3. Life expectancy > 3 months 4. Absence of brain metastasis 5. Age =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Brain metastasis 2. Active infections

Design outcomes

Primary

MeasureTime frame
Main Objective: 1. CHEMICAL: administration of the vaccine, clinical monitoring, clinical safety and efficacy, 2. BIOLOGICAL: methods of colture, evaluation of the biological efficacy,;Secondary Objective: 1. CHEMICAL: immunologic monitoring in vivo 2. BIOLOGICAL: critical and statistic evaluation of the results;Primary end point(s): Preparation of the vaccine antigenic format—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026